Import Substitution in Russia
RNC Pharma sums up the first wave of the analytical project “Monitoring of Import Substitution in Russia”. This is a detailed analysis of the intensity of import substitution in the most capital-intensive sectors, i.e. evaluation of the activity and depth of the localization of foreign pharmaceutical drugs in the Russian market.
The first wave of the project analyzed the 57 pharmaceutical drugs of strategic importance, the drugs on the 2015 VED list, and the drugs on the 2015 list of high-cost nosologies. Apart from those already available, 72 Russian alternatives to 33 INNs out of the 57 strategically important pharmaceutical drugs will appear in the Russian pharmaceutical market in 2015–2017, which confirms that import substitution is working. The role of the localization is relatively small, though, as foreign companies produce 22 out of the 57 strategically important drugs at Russian factories, with the full-cycle production of only 7 drugs.
As for the 2015 VED list, the situation for foreign companies is even more serious. At Russian factories, foreign companies produce only 69 drugs out of more than 600 INNs, with the full-cycle production of only 24 drugs.
If you would like the full report, please contact email@example.com